These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 20652801)
1. Soluble epithin/PRSS14 secreted from cancer cells contains active angiogenic potential. Kim SB; Lee D; Jeong JW; Kim C; Park D; Kim MG Mol Cells; 2010 Jun; 29(6):617-23. PubMed ID: 20652801 [TBL] [Abstract][Full Text] [Related]
2. PRSS14/Epithin is induced in macrophages by the IFN-γ/JAK/STAT pathway and mediates transendothelial migration. Lee D; Lee HS; Yang SJ; Jeong H; Kim DY; Lee SD; Oh JW; Park D; Kim MG Biochem Biophys Res Commun; 2011 Feb; 405(4):644-50. PubMed ID: 21295011 [TBL] [Abstract][Full Text] [Related]
3. A JUN N-terminal kinase inhibitor induces ectodomain shedding of the cancer-associated membrane protease Prss14/epithin via protein kinase CβII. Yoon J; Cho Y; Kim KY; Yoon MJ; Lee HS; Jeon SD; Cho Y; Kim C; Kim MG J Biol Chem; 2020 May; 295(20):7168-7177. PubMed ID: 32241917 [TBL] [Abstract][Full Text] [Related]
4. Intramembrane proteolysis of an extracellular serine protease, epithin/PRSS14, enables its intracellular nuclear function. Cho Y; Kim SB; Kim J; Pham AVQ; Yoon MJ; Park JH; Hwang KT; Park D; Cho Y; Kim MG; Kim C BMC Biol; 2020 Jun; 18(1):60. PubMed ID: 32493324 [TBL] [Abstract][Full Text] [Related]
5. Environment-Sensitive Ectodomain Shedding of Epithin/PRSS14 Increases Metastatic Potential of Breast Cancer Cells by Producing CCL2. Jang J; Cho EH; Cho Y; Ganzorig B; Kim KY; Kim MG; Kim C Mol Cells; 2022 Aug; 45(8):564-574. PubMed ID: 35950457 [TBL] [Abstract][Full Text] [Related]
6. Epithin/PRSS14 proteolytically regulates angiopoietin receptor Tie2 during transendothelial migration. Kim C; Lee HS; Lee D; Lee SD; Cho EG; Yang SJ; Kim SB; Park D; Kim MG Blood; 2011 Jan; 117(4):1415-24. PubMed ID: 21097670 [TBL] [Abstract][Full Text] [Related]
7. Shedding of epithin/PRSS14 is induced by TGF-β and mediated by tumor necrosis factor-α converting enzyme. Lee HS; Park BM; Cho Y; Kim S; Kim C; Kim MG; Park D Biochem Biophys Res Commun; 2014 Oct; 452(4):1084-90. PubMed ID: 25245289 [TBL] [Abstract][Full Text] [Related]
8. Targeting metastatic breast cancer with peptide epitopes derived from autocatalytic loop of Prss14/ST14 membrane serine protease and with monoclonal antibodies. Kim KY; Yoon M; Cho Y; Lee KH; Park S; Lee SR; Choi SY; Lee D; Yang C; Cho EH; Jeon SD; Kim SH; Kim C; Kim MG J Exp Clin Cancer Res; 2019 Aug; 38(1):363. PubMed ID: 31426843 [TBL] [Abstract][Full Text] [Related]
9. The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. Friedli A; Fischer E; Novak-Hofer I; Cohrs S; Ballmer-Hofer K; Schubiger PA; Schibli R; Grünberg J Int J Biochem Cell Biol; 2009 Jul; 41(7):1572-80. PubMed ID: 19401151 [TBL] [Abstract][Full Text] [Related]
10. Epithin, a target of transforming growth factor-beta signaling, mediates epithelial-mesenchymal transition. Lee HS; Kim C; Kim SB; Kim MG; Park D Biochem Biophys Res Commun; 2010 May; 395(4):553-9. PubMed ID: 20398629 [TBL] [Abstract][Full Text] [Related]
11. N-terminal processing is essential for release of epithin, a mouse type II membrane serine protease. Cho EG; Kim MG; Kim C; Kim SR; Seong IS; Chung C; Schwartz RH; Park D J Biol Chem; 2001 Nov; 276(48):44581-9. PubMed ID: 11567025 [TBL] [Abstract][Full Text] [Related]
12. Endothelial CD146 is required for in vitro tumor-induced angiogenesis: the role of a disulfide bond in signaling and dimerization. Zheng C; Qiu Y; Zeng Q; Zhang Y; Lu D; Yang D; Feng J; Yan X Int J Biochem Cell Biol; 2009 Nov; 41(11):2163-72. PubMed ID: 19782948 [TBL] [Abstract][Full Text] [Related]
13. Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (Prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer. Kim S; Yang JW; Kim C; Kim MG Oncotarget; 2016 Jun; 7(23):34643-63. PubMed ID: 27167193 [TBL] [Abstract][Full Text] [Related]
14. Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Brunet-Dunand SE; Vouyovitch C; Araneda S; Pandey V; Vidal LJ; Print C; Mertani HC; Lobie PE; Perry JK Endocrinology; 2009 Mar; 150(3):1341-52. PubMed ID: 18974274 [TBL] [Abstract][Full Text] [Related]
15. Matriptase/epithin participates in mammary epithelial cell growth and morphogenesis through HGF activation. Lee SL; Huang PY; Roller P; Cho EG; Park D; Dickson RB Mech Dev; 2010; 127(1-2):82-95. PubMed ID: 19853659 [TBL] [Abstract][Full Text] [Related]
16. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Bottos A; Martini M; Di Nicolantonio F; Comunanza V; Maione F; Minassi A; Appendino G; Bussolino F; Bardelli A Proc Natl Acad Sci U S A; 2012 Feb; 109(6):E353-9. PubMed ID: 22203991 [TBL] [Abstract][Full Text] [Related]
17. Danshensu has anti-tumor activity in B16F10 melanoma by inhibiting angiogenesis and tumor cell invasion. Zhang LJ; Chen L; Lu Y; Wu JM; Xu B; Sun ZG; Zheng SZ; Wang AY Eur J Pharmacol; 2010 Sep; 643(2-3):195-201. PubMed ID: 20621088 [TBL] [Abstract][Full Text] [Related]
18. Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo. Webb SL; Sanders AJ; Mason MD; Jiang WG Mol Cell Biochem; 2013 Mar; 375(1-2):207-17. PubMed ID: 23238872 [TBL] [Abstract][Full Text] [Related]
19. Shedding of membrane epithin is blocked without LDLRA4 and its protease activation site. Cho EG; Schwartz RH; Kim MG Biochem Biophys Res Commun; 2005 Feb; 327(1):328-34. PubMed ID: 15629466 [TBL] [Abstract][Full Text] [Related]
20. ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signalling. Banerjee A; Wu ZS; Qian PX; Kang J; Liu DX; Zhu T; Lobie PE PLoS One; 2012; 7(11):e50098. PubMed ID: 23185544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]